ES2143620T3 - Polipeptidos modificados con actividad biologica incrementada. - Google Patents

Polipeptidos modificados con actividad biologica incrementada.

Info

Publication number
ES2143620T3
ES2143620T3 ES95912917T ES95912917T ES2143620T3 ES 2143620 T3 ES2143620 T3 ES 2143620T3 ES 95912917 T ES95912917 T ES 95912917T ES 95912917 T ES95912917 T ES 95912917T ES 2143620 T3 ES2143620 T3 ES 2143620T3
Authority
ES
Spain
Prior art keywords
modified polypeptides
biological activity
increased biological
increased
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912917T
Other languages
English (en)
Inventor
Arthur J Sytokowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Beth Israel Deaconess Medical Center Inc
Application granted granted Critical
Publication of ES2143620T3 publication Critical patent/ES2143620T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DESCRIBEN POLIPEPTIDOS MODIFICADOS CON ACTIVIDAD BIOLOGICA AUMENTADA MOSTRADA BIEN COMO POTENCIA AUMENTADA O COMO VIDA MEDIA DE CIRCULACION PROLONGADA CON METODOS DE PREPARACION DE LOS POLIPEPTIDOS MODIFICADOS Y METODOS DE USO.
ES95912917T 1994-03-22 1995-03-15 Polipeptidos modificados con actividad biologica incrementada. Expired - Lifetime ES2143620T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/216,259 US5580853A (en) 1994-03-22 1994-03-22 Modified polypeptides with increased biological activity

Publications (1)

Publication Number Publication Date
ES2143620T3 true ES2143620T3 (es) 2000-05-16

Family

ID=22806382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912917T Expired - Lifetime ES2143620T3 (es) 1994-03-22 1995-03-15 Polipeptidos modificados con actividad biologica incrementada.

Country Status (9)

Country Link
US (1) US5580853A (es)
EP (1) EP0751959B1 (es)
AT (1) ATE188486T1 (es)
DE (1) DE69514342T2 (es)
DK (1) DK0751959T3 (es)
ES (1) ES2143620T3 (es)
GR (1) GR3033146T3 (es)
PT (1) PT751959E (es)
WO (1) WO1995025746A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1997035560A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved echogenic liposome compositions
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
EA003922B1 (ru) * 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
EP1591453A1 (en) * 1999-05-17 2005-11-02 ConjuChem Inc. Modified peptides yy and conjugates thereof
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2379388C (en) * 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
CA2423093C (en) 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
CN1491233A (zh) * 2001-02-02 2004-04-21 康久化学公司 长效生长激素释放因子衍生物
JP4280070B2 (ja) * 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
EP1613274B1 (en) 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
WO2004101611A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
SI1629007T1 (sl) * 2003-05-12 2009-10-31 Affymax Inc Novi peptidi, ki se veĹľejo na eritropoetinski receptor
EP1628686A2 (en) * 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
EP1626983B8 (en) * 2003-05-12 2010-12-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
PT2100904E (pt) 2004-04-23 2010-09-24 Conjuchem Biotechnologies Inc Fase sólida para utilização num método para a purificação de conjugados de albumina
CA2587382A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006063055A2 (en) * 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
EP2364995A1 (en) * 2004-12-23 2011-09-14 Molmed SpA Conjugation product
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
SI2437790T1 (sl) 2009-06-03 2019-07-31 Immunogen, Inc. Konjugacijske metode
EA201991268A3 (ru) 2011-03-29 2020-01-31 Иммуноджен, Инк. Получение конъюгатов "майтансиноид-антитело" одностадийным способом
US9243049B2 (en) 2011-08-09 2016-01-26 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
GR3033146T3 (en) 2000-08-31
US5580853A (en) 1996-12-03
PT751959E (pt) 2000-06-30
DE69514342T2 (de) 2000-11-30
DK0751959T3 (da) 2000-06-26
EP0751959A1 (en) 1997-01-08
ATE188486T1 (de) 2000-01-15
DE69514342D1 (de) 2000-02-10
WO1995025746A1 (en) 1995-09-28
EP0751959B1 (en) 2000-01-05

Similar Documents

Publication Publication Date Title
ES2143620T3 (es) Polipeptidos modificados con actividad biologica incrementada.
DE3876839D1 (de) Stuhl- und wagenkombination.
DE68924026D1 (de) Biosensor und dessen herstellung.
NO952039D0 (no) Proteiner med glykosyltransferase-aktivitet
DK96787A (da) Human vaevs-plasminogenaktivator
DK267885A (da) Maebel, saasom sidde- eller liggemaebel
DE69010317D1 (de) Acrylgel und seine Herstellung.
DE3682882D1 (de) Menschliches immunoglobulin-g-fc-region-protein und dessen herstellung.
DE3674789D1 (de) Balken und dessen herstellung.
DE3881099D1 (de) Acrylkautschuk, zusammensetzung aus acrylkautschuk und gegenstaende aus vernetztem acrylkautschuk.
DE3586952D1 (de) Fibrinophiler urokinase-komplex und dessen herstellung.
DK538589D0 (da) Baktericidt middel
DE69012958D1 (de) Fibrinolytisches Protein und Herstellungsweise dafür.
KR890015933U (ko) 회전의자
NO900606D0 (no) Enzymatisk oppvask- og skyllemiddel.
KR880014653U (ko) 회전 의자
KR850007051U (ko) 요동식 침대의자
ATE57223T1 (de) Balken und dessen herstellung.
FI864087A0 (fi) Lampenhet foer baerroer i belysningsanordning.
KR910002156U (ko) 회전의자
IT210126Z2 (it) Sedia con spalliera inclinabile
IT8619477A0 (it) Sostanza ad attivita'nootropa e psicostimolante.
AU608232C (en) Modified tissue plasminogen activator
ES540569A0 (es) Perfeccionamientos introducidos en la construccion de inver-naderos.
ATE96315T1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751959

Country of ref document: ES